Podcasts about Rahul

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Attack on Yogi, T Raja Singh's exit, Kejriwal's Punjab dreams & Rahul's Congress crisis, Harsh Kumar joins Sanjay Dixit to decode BJP's caste bets in UP, Delhi's bulldozers & Punjab's AAP surge.

Martin and Rahul are back to talk about the incredible 3x3 World Cup that took place in Ulaanbaatar this past week, covering all from the magical run of Mongolia to the hits and misses from the event. They also talk about a very special 3x3 event coming up, tune in to find out more!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial. Join us as we explore: • The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate. • The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment. • Key findings from the Luminosity trial, including response rates and study design. • The importance of C-met testing in clinical practice. • Management of side effects associated with telisotuzumab, particularly peripheral neuropathy. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!

AI without a data science team? It's not a fantasy it's the future.In this week's SaaS Fuel episode, Jeff Mains sits down with Rahul Pangam, CEO of RapidCanvas and former VP at PayPal, to explore how AI is becoming accessible to every SaaS founder no code required.We dive deep into the enterprise AI dilemma: where to start, what ROI to expect, and how to avoid wasting budget on hype. Rahul shares how RapidCanvas is transforming messy, unstructured data into real-time insights for non-technical users, and the hard-earned startup lessons that shaped this vision.If you're sitting on data gold but don't know how to mine it, this episode is your blueprint for action.Key Takeaways00:00 - The AI dilemma: start now or risk falling behind?01:09 - Welcome to SaaS Fuel01:38 - What if you could build AI without writing code?02:28 - AI is being democratized—finally03:15 - Recap: Patricia Fripp & Andrew Seidman episodes04:03 - Meet Rahul Pangam of RapidCanvas05:05 - From PayPal to RapidCanvas: Rahul's journey10:59 - What problem does RapidCanvas solve?16:27 - Pairing digital intelligence with domain expertise19:18 - Why outcomes—not code—drive AI adoption20:35 - Is AI only for big tech? How it's being democratized23:58 - Turning PDFs into insight without tech skills25:48 - Hard lessons from Rahul's first startup28:52 - From startup to PayPal: what corporate taught him33:58 - Hiring & product mistakes that left a mark37:39 - Scaling stage: can everyone grow with the company?39:09 - How to build trust in skeptical buyers44:21 - Should AI be on your roadmap? Ask this question47:01 - Where does AI fit in your org?50:14 - Where to find Rahul & RapidCanvas online51:55 - Cupcakes, Series A sprinkles & future guestsTweetable Quotes“If you don't do AI, your board asks why. If you do, you wonder where to even start.” — Rahul Pangam“You don't need a data science degree to use AI—you need the right platform.” — Jeff Mains“AI isn't about writing code. It's about delivering outcomes.” — Rahul Pangam“Stop chasing trends. Start solving real problems with real data.” — Jeff Mains“The most valuable startups don't build tools—they deliver results.” — Rahul Pangam“Data alone isn't an asset until you can act on it.” — Jeff MainsSaaS Leadership LessonsYou don't need a data team to implement AI.Natural language platforms like RapidCanvas are bridging the tech gap.Most leaders don't lack data—they lack clarity.Turning information into insight is where real transformation starts.AI adoption must be outcome-driven.Focus on business impact, not fancy features or buzzwords.Founders must guide AI from concept to outcome.Even no-code tools need leadership to shape direction and alignment.Startup scars shape smart strategy.Rahul's lessons from Simility highlight the value of postmortem reflection and iteration.AI implementation isn't about automation—it's about acceleration.It's not about replacing people. It's about empowering decision-makers faster.Guest ResourcesEmail - rahul@rapidcanvas.aiWebsite - http://rapidcanvas.ai/LinkedIn - https://www.linkedin.com/in/rahulpangam/Episode...

India 471 (Gill 147, Pant 134, Jaiswal 101) & 364 (Rahul 137, Pant 118; Tongue 3-72) England 465 (Pope 106, Brook 99, Bumrah 5-83) & 373-5 (Duckett 149, Crawley 65, Root 53*) England win by five wickets, and lead the five-match series 1-0 Test cricket at its finest on Day 5 of the first Test with one of the all time great run chases as England, in no small part thanks to an incredible 149 by Ben Duckett, who shared a 1st wicket stand of 188 with Zak Crawley, beat India by 5 wickets. Dan and Toby reflect on a day that will live long in the memory. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Industrial Talk is onsite at Hexagon LIVE and talking to Kyle Wessells, Rahul Shinde, Ryan McOdrum and Matthew Peak at Hexagon ALI about "Game changing asset management platform". Scott MacKenzie hosts the Industrial Talk podcast, featuring discussions on industry innovations and trends. At Hexagon Live in Las Vegas, MacKenzie highlights the Asset Life Cycle Intelligence (ALI) platform and Asset Performance Management (APM) solutions. ALI integrates smart 3D design with SDx2 for continuous data synchronization, enhancing asset management. Hexagon EAM, a configurable system for enterprise asset management, supports compliance across various industries. APM uses machine learning to predict asset health and integrate sensor data, aiding in proactive maintenance. The conversation emphasizes the importance of data continuity and the role of AI in improving operational efficiency. Action Items [ ] Reach out to Rahul Shinde (Senior Solutions Consultant at Hexagon) on LinkedIn or at rahul.shinde@hexagon.com to learn more about the integration of 3D design tools and STX2. [ ] Connect with Ryan McOdrum (Sr. Solutions Consultant at Hexagon) on LinkedIn or at ryan.mcodrum@hexagon.com to discuss Hexagon EAM and its configurability. [ ] Follow up with Matt Peak (Solution Consultant at Hexagon) on LinkedIn or at matt.peak@hexagon.com to understand the integration of Hexagon EAM, APM, and J5 Operations Management. Outline Hexagon Live Event Overview Scott MacKenzie introduces the Industrial Talk Podcast and its focus on industry innovations and trends. Scott MacKenzie recaps the Hexagon Live event in Las Vegas, highlighting the innovations and solutions showcased. Scott MacKenzie mentions the Asset Life Cycle Intelligence Platform (ALI) from Hexagon and its significance. Scott MacKenzie promotes an ebook and a workbook available for free download on the Industrial Talk website. Introduction to ALI and APM Scott MacKenzie discusses the importance of ALI and APM (Asset Performance Management) in providing greater insights into assets and business operations. Scott MacKenzie introduces Kyle and mentions the interactive art gallery at Hexagon Live. Kyle explains the interactive art gallery's purpose in representing visibility and value drivers. Kyle introduces the smart 3D design solution and its integration with SDx2, emphasizing data synchronization and contextualization. Smart 3D and SDx2 Integration Rahul explains the integration of smart 3D and SDx2, including data synchronization from P&IDs and 3D models. Scott MacKenzie inquires about the digitization of P&IDs and the use of legacy data. Rahul details the process of digitizing P&IDs and synchronizing data to SDx2 for better management and maintenance. Rahul highlights the business rationale behind the integration, including the use of design tools for maintenance and operations. Business Rationale and Implementation Rahul explains the business rationale for using design tools in maintenance and operations, enhancing sustainability. Scott MacKenzie asks about the journey to achieving a common record for accurate data management. Rahul outlines the infrastructure requirements for connecting design solutions to SDx2 and the benefits of a secure, scalable solution....

Abhishek Tiwari joins Sanjay Dixit to decode Modi's triple-front assault: geopolitical dominance, Bihar battlefield, and internal BJP resets. Rahul stumbles, opposition cracks, while Modi's East push and Shah–Yogi pact redraw the game.

India 471 (Gill 147, Pant 134, Jaiswal 101) & 364 (Rahul 137, Pant 118; Tongue 3-72) England 465 (Pope 106, Brook 99, Bumrah 5-83) & 21-0 England need 350 more runs, India need 10 wickets Centuries from KL Rahul and Rishabh Pant and three wickets in four deliveries by Josh Tongue's has put the First Test in a position where all four results are possible on the final day. India were all out for 364 in their second innings, losing their last six wickets for 31 runs. England will need to pull off their second highest successful run chase in Test to take a 1-0 lead in the five match series. Toby and Dan look back on the day in an episode that took a surprising turn... Learn more about your ad choices. Visit podcastchoices.com/adchoices

Actor, activist, and passionate rugby advocate Rahul Bose joins Cyrus for an energetic and engaging episode of Cyrus Says. The two dive into a spirited conversation about the newly launched Rugby Premier League, with Rahul breaking down its vision, structure, and why he believes India — and specifically Mumbai — is the perfect ground to kick off this sporting revolution. Beyond the game, the episode is packed with laughs as Rahul and Cyrus explore the art of accents, perform impromptu impressions, and riff off each other’s wit. Equal parts informative and entertaining, this episode is a treat for sports lovers, rugby newbies, and long-time fans of Cyrus' trademark chaos.See omnystudio.com/listener for privacy information.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute to discuss the latest breakthroughs in breast cancer presented at the ASCO 2025 annual meeting. We dived into five key abstracts that could change the landscape of breast cancer treatment: 1.⁠ INAVO120: observed overall survival data with the combination of inavolisib, with palbociclib and fulvestrant for patients with PIK3CA mutated hormone receptor-positive, HER2-negative advanced breast cancer. 2.⁠ ⁠SERENA-6: camizestrant use in patients with emerging ESR1 mutations using ctDNA, showed significant improvement in progression-free survival. 3.⁠ ⁠VERITAC-2: vepdegestrant showed superior progression-free survival compared to fulvestrant, particularly in ESR1 mutated patients. 4.⁠ ⁠DESTINY-Breast09: significant improvement in progression-free survival with TDXd plus pertuzumab in frontline HER2-positive metastatic breast cancer, challenging the traditional CLEOPATRA regimen THP. 5.⁠ ⁠ASCENT-04: promising results of sacituzumab combined with pembrolizumab in PD-L1 positive triple-negative breast cancer. Join us for an insightful discussion on these practice changing/informing studies and their implications for clinical practice.  YouTube: https://youtu.be/5XvrOn2p0jc Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more updates on treatment algorithms, recent approvals, and conference highlights!

Chris Davies is joined by Rahul Gupta. Rahul is a 27-year-old Deaf individual who works as a pharmacy technician at the Mayo Clinic, with two years of hands-on experience supporting in-patient care and pharmacy operations. Rahul, who is fluent in both American Sign Language (ASL) and English, has become a strong self-advocate who is dedicated to empowering Deaf and Hard of Hearing (DHH), Deaf Blind, and other individuals to recognize their potential, build meaningful lives, and set and achieve their personal goals.

Discover the entrepreneurial journey of Rahul Veerwal, the founder and CEO of GetWork. From his experiences managing placements at NIT Allahabad to building an AI-driven hiring platform impacting thousands of students across India, Rahul shares valuable insights on the challenges fresh graduates face, the impact of AI on job opportunities, and his vision for empowering the next generation of talent. We discuss the evolution of GetWork, their go-to-market strategy, and the future of recruitment in a rapidly changing world.

After a lot of hype and expectations for this season. Sunrisers Hyderabad had a disappointing season as they failed to make it to the top 4. How did it go wrong?Where was the trouble?Tune in as we review the SRH 2025 season with Rahul from Cricket Nagram Podcast.

Tous les 1er dimanches de chaque mois, découvre l'histoire d'une vie, une expérience ou un moment clé d'une femme ou d'un homme. Fais connaissance avec une ou un Passeur de Clés qui te donnera sa vision et son approche. Pars en balade avec nous et profite de ce moment intimiste et confidentiel pour, qui sait, découvrir les clés de vie qui te manquent ! ************************************************************** Rahul BHARTI Plus d'infos : www.thehealinghandscenterinternational.com www.instagram.com/thehealinghandscenter/?hl=fr LA PARENTHÈSE MUSICALE "Aum" de BARRUECO Plus d'infos : https://barrueco.fr/ www.youtube.com/barruec COUP DE CŒUR FILM DE RAHUL "Indiana Jones et la dernière croisade" de Steven SPIELBERG Plus d'infos : www.youtube.com/watch?v=ZVAxDZVHGyg COUP DE CŒUR MUSIQUE DE RAHUL "Ain't got no, I got life" de Nina SIMONE Plus d'infos : www.youtube.com/watch?v=L5jI9I03q8E COUP DE COEUR LIVRE DE RAHUL "Le livre tibétain de la vie et de la mort" de Plus d'infos : www.youtube.com/watch?v=VyPwBIOL7-8

This week, host Avdhesh Kumar is joined by Newslaundry's Sumedha Mittal, BBC's Abhinav Goel and reporter Akansha Kumar. Abhinav presents an in-depth report on the true death toll of the Mahakumbh Mela tragedy that happened in January. While the Uttar Pradesh government has officially acknowledged 37 deaths due to the stampede, BBC's investigation has uncovered at least 82 fatalities so far. Despite government promises, many of the victims' families have yet to receive the promised compensation.Akansha uncovers allegations of police impunity in Kaushambi in Uttar Pradesh. Her deep dive into police encounters in Uttar Pradesh reveal chilling accounts from families who lost loved ones in suspected extrajudicial killings.Several families allege that police not only carried out unlawful encounters but also attempted to silence them with bribes. Many of these encounters took place in the same location: Goonghwa Ka Bagh in Kaushambi. Affected families are running from pillar to post in their fight for justice and accountability.Meanwhile, Sumedha brings a sharply different story from Delhi. Since his appointment as Lieutenant Governor in May 2022, VK Saxena was known for publicly targeting the AAP-led government over civic issues. However, his stance appears to have softened following the BJP's rise to power in February 2025.Sumedha's report explores this shift in tone – tracing how the LG's confrontational approach has evolved and what it reveals about the changing political dynamics in the capital.Timecodes00:00:00 - Introduction00:01:04 - Beyond 82: The Controversy Over Kumbh Stampede Casualties00:31:20 - Encounter Raj in UP: A Deep Dive into Its Persistent Reality00:52:24 - Dynamics Between Delhi's LG and the Ruling Party: An observer's view00:59: 58 - RecommendationsRecommendationsAbhinavThe Unwomanly Face of WarThe Sharp Knife of MemorySumedha Rahul Gandhi writes: Match-fixing MaharashtraToday in Politics: Congress to make people aware of Rahul's ‘fixing polls claims' with processions across MaharashtraAkansha Among the Trolls: My Journey Through ConspiracylandAvdheshDr. Ambedkar: Life And MissionProduced and edited by Hassan Bilal and Tista Roy Chowdhury, recorded by Anil Kumar. Hosted on Acast. See acast.com/privacy for more information.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies. Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment: 1.⁠ ⁠DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity. 2.⁠ ⁠ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50. 3.⁠ ⁠BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months. 4.⁠ ⁠MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival. 5.⁠ ⁠DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma. YouTube: https://youtu.be/hllyI5S2Dqg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.

What does it take to drive product innovation in industries that aren't traditionally product-led?Heather Samarin and Vidya Dinamani sit down with Rahul Nath, CPO at Accel, who brings rich experience from Google, Drip Capital, and McKinsey. Rahul shares how he builds product in non-product-led spaces, from redefining onboarding in trade finance to leveraging AI in venture capital. Hear Rahul's practical lessons on stakeholder alignment, scrappy experimentation, data-driven decision-making, and why he believes “if there's no clear strategy—write one.” A must-listen for product leaders navigating ambiguity and driving bold transformation.

WE APPRECIATE EACH AND EVERY ONE OF YOU! If you wouldn't mind please go leave us a review on Apple Podcasts! Thanks!!Welcome back to Episode 359 of On the Spot Sports and in today's episode we have a very special guest, Danbury Hat Tricks goaltender, Rahul Sharma! Rahul and I talk about his first year of professional hockey in the FPHL. We also talk about the process of going from practice goalie to starting games, falling in love with the process, having faith and belief in what you do, growth as a person and athlete, finding ways to get better every day, Junior hockey and continuing to push greatness despite slow starts, coming back to hockey after an injury and so much more! We hope you guys enjoy this episode!!Thank you Rahul for coming on the show! I had a blast!!Follow us on Instagram @on_the_spot_sports and take a listen on YouTube, Spotify and Apple/Google Podcasts @ On The Spot SportsGet $25 off our guy Jamie Phillips Nutrition book for Hockey Players with the discount code "ONTHESPOT" on victoremnutrition.comLiving Sisu link: ⁠⁠https://livingsisu.com/app/devenirmem.... BECOME A MEMBER TODAY

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer. Join us as we dive into five key studies that could change clinical practice: 1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer. 2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes. 3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies. 4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates. 5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights! #OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast

Our guests are Rahul Saito and Mitsu Nagae.  Rahul is the owner and Mitsu is the co-owner and executive chef at l'abeille https://www.labeille.nyc and l'abeille à côté https://www.labeilleacote.nyc/ in Tribeca, New York. The duo opened l'abeille in March 2022 and shortly after, they won a Michelin star, thanks to Mitsu's unique and outstanding culinary background as a Japanese chef classically trained in Paris, Tokyo and New York as well as Rahul's sound management despite being new to the industry. Mitsu's menus are characterized by a seamless merge of French and Japanese cuisines, which seems to have become a relevant genre in places like Paris and Japan as well. In this episode, we will discuss how Mitsu got into French cuisine from a young age in Japan and eventually trained under top chefs like the late Joel Robuchon, why the seemingly opposite French and Japanese cuisines can go so well together as you can see in Mitsu's menus, the keys to run successful restaurants in New York and much, much more!!!

Rahul Jandial, MD, PhD, is a dual-trained brain surgeon and neuroscientist at City of Hope in Los Angeles, California. Before finding his calling in the operating room, Dr. Jandial was a college dropout and worked as a security guard. As a surgeon, he now provides complex surgical treatment to patients with cancer. As a scientist, his laboratory investigates the biology of the human brain. Throughout his career, he has authored 10 books and over 100 academic articles.Take action and strengthen your mind with The Resilient Mind Journal. Get your free digital copy today: ⁠⁠⁠⁠⁠https://bit.ly/Download_JournalSpecial thanks to Lewis Howes, subscribe to his channel here: https://www.youtube.com/c/lewishowesWatch the full interview on Lewis's page: https://www.youtube.com/watch?v=JYalx8bvEyg Hosted on Acast. See acast.com/privacy for more information.

Dan and Ellen talk with Rahul Bhargava, a colleague at Northeastern University. Rahul is a professor who crosses boundaries: the boundaries of storytelling and data, the boundaries of deep dives into collaborative research and interactive museum exhibits and plays. He holds a master's degree in media arts and science from MIT, and a bachelor's degree in electrical and computer engineering from Carnegie Mellon University. But he also minored in multimedia production. He brings the power of big data research to the masses, through newsroom workshops, interactive museum exhibits, and more. Rahul has collaborated with groups in Brazil, in Minnesota and at the World Food Program. He helps local communities use data to understand their world, and as a tool for change. There's more to data than just bar charts. Sometimes it involves forks! His book, "Community Data," unlocks all sorts of secrets. Dan and Ellen also talk with Lisa Thalhamer, a longtime TV journalist who is now a graduate student at Northeastern. Lisa realized that like many fields, journalism suffers from a gap between academic research and its implementation in workplaces. She is finding ways to bridge that gap, and urges an Avenger's-style team to lift up the work of a free press. Ellen has a Quick Take on a recent visit to Santa Barbara, California, and the efforts to revive a legacy paper, the Santa Barbara News-Press. Dan's Quick Take is about the latest development from the National Trust for Local News. It involves a chain of weekly papers in Colorado — their very first acquisition dating back to 2021. And it's not good news at all for the journalists who work at those papers and the communities they serve.  

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study. Join us as we delve into: •⁠  ⁠The significance of MSI-high status in colorectal cancer and its prevalence. •⁠  ⁠The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates. •⁠  ⁠The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy. •⁠  ⁠Important side effects associated with the combination therapy and how to manage them. •⁠  ⁠Insights on patient selection for immunotherapy, including considerations for age and comorbidities. •⁠  ⁠The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment. YouTube: https://youtu.be/wJRlECiY2VA Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025! #OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW

Technology isn't just a sector anymore—it's the driving force reshaping every industry. Whether companies are creating technology or adopting it to avoid disruption, understanding this transformation is crucial for investment success.Columbia Threadneedle's tech investment approach stands apart through its disciplined focus on three complementary buckets: moat-type businesses with sustainable competitive advantages, secular growth themes identified early, and value opportunities where market prices underestimate business quality. This balanced strategy has consistently generated top-tier returns, with their technology portfolio ranking in Morningstar's top third for 8 of the past 12 years.What truly distinguishes their approach is patience. With just 7% annual turnover, they allow investments in companies like Microsoft, Apple, Amazon, and NVIDIA to compound over many years. This long-term perspective proves especially valuable when navigating tech's inherent volatility. As portfolio manager Rahul explains, even AI—their largest investment theme since 2016—has experienced two 20% pullbacks in the last 18 months alone.Recent earnings revealed tech's continued strength, with mega-cap tech growing earnings 28% versus just 9% for the remainder S&P 493. Cloud infrastructure spending is projected to reach $390 billion this year, nearly nine times higher than a decade ago. While tariffs pose the most significant current risk, particularly for semiconductors, the team's diversified approach and deep research capabilities help manage these challenges.With technology now representing 31% of the S&P 500 and nearly half the Russell 1000 Growth Index, investors increasingly recognize the value of specialist management in this complex sector. Columbia Threadneedle's recently launched Select Technology ETF (SEMI) offers another vehicle to access their expertise alongside their established funds.Ready to enhance your portfolio with professional technology exposure? Visit Columbia Threadneedle's website to explore their SEMI ETF and discover how their research-driven approach can help navigate technology's opportunities and challenges.With ChatDOC, instantly analyze professional documents using AI — featuring word-level citations, chart/formula breakdowns, cross-file query, and full support for PDFs/epub/scanned files.Free version handles 10 documents (up to 3000 pages) and cross-searches 30 files.Click the link below to unlock +10 document slots : https://chatdoc.com?src=leadlaglive Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Support the show

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: •⁠  ⁠The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. •⁠  ⁠Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. •⁠  ⁠Strategies for managing these side effects to improve patient quality of life and treatment adherence. •⁠  ⁠Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!

Demetrios, Sam Partee, and Rahul Parundekar unpack the chaos of AI agent tools and the evolving world of MCP (Model Context Protocol). With sharp insights and plenty of laughs, they dig into tool permissions, security quirks, agent memory, and the messy path to making agents actually useful.// BioSam ParteeSam Partee is the CTO and Co-Founder of Arcade AI. Previously a Principal Engineer leading the Applied AI team at Redis, Sam led the effort in creating the ecosystem around Redis as a vector database. He is a contributor to multiple OSS projects including Langchain, DeterminedAI, LlamaIndex and Chapel amongst others. While at Cray/HPE he created the SmartSim AI framework which is now used at national labs around the country to integrate HPC simulations like climate models with AI. Rahul ParundekarRahul Parundekar is the founder of AI Hero. He graduated with a Master's in Computer Science from USC Los Angeles in 2010, and embarked on a career focused on Artificial Intelligence. From 2010-2017, he worked as a Senior Researcher at Toyota ITC working on agent autonomy within vehicles. His journey continued as the Director of Data Science at FigureEight (later acquired by Appen), where he and his team developed an architecture supporting over 36 ML models and managing over a million predictions daily. Since 2021, he has been working on AI Hero, aiming to democratize AI access, while also consulting on LLMOps(Large Language Model Operations), and AI system scalability. Other than his full time role as a founder, he is also passionate about community engagement, and actively organizes MLOps events in SF, and contributes educational content on RAG and LLMOps at learn.mlops.community.// Related LinksWebsites: arcade.devaihero.studio~~~~~~~~ ✌️Connect With Us ✌️ ~~~~~~~Catch all episodes, blogs, newsletters, and more: https://go.mlops.community/TYExploreMLOps Swag/Merch: [https://shop.mlops.community/]Connect with Demetrios on LinkedIn: /dpbrinkmConnect with Rahul on LinkedIn: /rparundekarConnect with Sam on LinkedIn: /samparteeTimestamps:[00:00] Agents & Tools, Explained (Without Melting Your Brain)[09:51] MVP Servers: Why Everything's on Fire (and How to Fix It)[13:18] Can We Actually Trust the Protocol?[18:13] KYC, But Make It AI (and Less Painful)[25:25] Web Automation Tests: The Bugs Strike Back[28:18] MCP Dev: What Went Wrong (and What Saved Us)[33:53] Social Login: One Button to Rule Them All[39:33] What Even Is an AI-Native Developer?[42:21] Betting Big on Smarter Models (High Risk, High Reward)[51:40] Harrison's Bold New Tactic (With Real-Life Magic Tricks)[55:31] Async Task Handoffs: Herding Cats, But Digitally[1:00:37] Getting AI to Actually Help Your Workflow[1:03:53] The Infamous Varma System Error (And How We Dodge It)

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University. In this episode, we covered: •⁠  Current treatment paradigm of small cell lung cancer, in localized setting and extensive stage. •⁠  ⁠We covered the recent approval of durvalumab in limited stage setting post chemoRT. •⁠  We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib. •⁠ Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab •⁠  Talked about logistical issues and uptake of Tarlatamab post approval. •⁠  Stressed the importance of clinical trials to move the field ahead. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

This episode, the chaos begins with names—Jim Sarbh explains the minimal effort behind his naming, while Amit Sadh reveals how his was the first thing that must’ve popped into his parents' heads. From there, it’s a deep dive into their backgrounds—Jim’s posh Mumbai schooling and expat education, and Amit’s roots in Lucknow and a couple other places, his dad’s sports legacy, and a shared alma mater with Cyrus. The trio bond over their football allegiances (Liverpool, Man Utd, Arsenal—civil war!), working on Pune Highway with Rahul and Bugs, and a surprising amount of love for biking, animals, and awkward film screenings. We also get stories from their first films (Kai Po Che, Neerja), biking as therapy, illegal rallies, acting school camaraderie, and one wildly specific joke comparing Cyrus to a Cyprus tree. It's raw, real, and very Cyrus Says.See omnystudio.com/listener for privacy information.

In this episode of Marketing Mindset, I'm joined by Rahul, Head of Paid Marketing at a performance agency managing 7–9 figure brands. Why hook rate and CTR don't always predict performanceHis exact reporting structure for tracking new customer growthA scrappy influencer hack that landed his brand in front of A-list celebritiesHow to iterate creative the right way (hint: it's not headline swaps) We unpack what actually matters in creative testing, reporting, and scaling spend.Rahul shares:We also get real about creative fatigue, why Meta's definition of a “new” asset has changed, and what to track when performance drops, plus the one question you must ask founders before building a report.

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

What happens when access to advanced AI models is no longer the real differentiator, and the true advantage lies in how businesses leverage their own data? At the AWS Summit in London, I sat down with Rahul Pathak, Vice President of Data and AI Go-to-Market at AWS, to unpack this question and explore how organisations are moving beyond experimentation and into large-scale generative AI adoption. Recorded live on the show floor, this conversation explores how AWS is supporting customers at every layer of their AI journey. From custom silicon innovations like Trainium and Inferentia to scalable services like Bedrock, Q Developer, and SageMaker, AWS is giving businesses the infrastructure, tools, and flexibility to innovate with confidence. Rahul shared how leading organisations such as BT Group, SAP, and Lonely Planet are already applying these tools to reduce costs, speed up development cycles, and deliver tailored experiences that would have been unthinkable just a few years ago. A key theme that emerged in our discussion is that data, not just models, is the true foundation of effective AI. Rahul explained why unifying data across silos is critical and how AWS is helping companies create more intelligent applications by connecting what they uniquely know about their business to powerful AI capabilities. We also addressed the operational realities of AI deployment. From moving proof-of-concept projects into production to meeting the growing demand for responsible AI, the challenges are shifting. Organisations are now focused on trust, security, transparency, and measurable value. If you're leading digital transformation and wondering how to scale AI solutions that deliver on business outcomes, this episode provides practical insight from someone at the center of the industry. How will your business stand out in a world where every company has access to AI models, but only a few know how to apply them with purpose?

Fluent Fiction - Hindi: Spring Blooms: Utopian Festival Unites Hearts and Arts Find the full episode transcript, vocabulary words, and more:fluentfiction.com/hi/episode/2025-05-13-22-34-02-hi Story Transcript:Hi: फूलों की खुशबू और संगीत की मधुर धुन ने पूरे माहौल को खुशनुमा बना दिया था।En: The fragrance of flowers and the melodious tunes of music had made the whole atmosphere delightful.Hi: वसंत के इस खूबसूरत मौसम में, एक शानदार उत्सव शहर के केंद्र में सज रहा था।En: In this beautiful season of spring, a grand festival was taking place in the city center.Hi: यह था यूटोपियन समाज सांस्कृतिक महोत्सव, जहाँ हर तरफ रंग-बिरंगी सजावट और खुशियों की झंकार थी।En: It was the Utopian Society Cultural Festival, where colorful decorations and the sound of joy were everywhere.Hi: अनन्या, एक युवा लड़की, जो पारंपरिक नृत्य की दीवानी थी, महोत्सव के मंच पर अपनी कला दिखाने के लिए उत्सुक थी।En: Ananya, a young girl who was passionate about traditional dance, was eager to showcase her art on the festival stage.Hi: मगर उसके दिल में एक डर भी था, मंच पर जाने का।En: But there was also a fear in her heart—of going on stage.Hi: दूसरी ओर, राहुल एक खामोश कलाकार था जो प्रेरणा की तलाश में था।En: On the other hand, Rahul was a quiet artist seeking inspiration.Hi: उसके दिल में भी एक उलझन थी—वास्तविक संबंध की खोज।En: He too had a dilemma in his heart—the search for a real connection.Hi: इस रंगीन माहौल के बीच, अनन्या मशहूर कत्थक नृत्यांगना सावित्री देवी के स्टॉल के पास खड़ी थी।En: Amidst this colorful environment, Ananya stood near the stall of the famous Kathak dancer Savitri Devi.Hi: उसके मन में विश्वास और भय का मिश्रण था।En: A mix of confidence and fear was in her mind.Hi: उधर, राहुल, अपने चित्रकला के लिए नई प्रेरणा की खोज में, उसी स्टॉल की तरफ बढ़ा।En: Meanwhile, Rahul, in search of new inspiration for his paintings, headed towards the same stall.Hi: अचानक उनकी नजरें मिलीं और एक हल्की मुस्कान ने दोनों के बीच संवाद शुरू किया।En: Suddenly, their eyes met, and a faint smile initiated a conversation between them.Hi: अनन्या ने मेज पर रखे नृत्य से जुड़े वस्त्रों को देखते हुए कहा, "ये लहंगा कितना सुंदर है, न?En: Looking at the dance-related garments on the table, Ananya said, "Isn't this lehenga beautiful?"Hi: " राहुल, उसकी बात सुनते ही थोड़ा मुस्कुराया और बोला, "हां, यह अद्भुत है।En: Rahul, upon hearing her, smiled a little and said, "Yes, it is wonderful.Hi: आप इसे पहनकर जरूर शानदार लगेंगी।En: You will definitely look magnificent wearing it."Hi: "अनन्या ने सहमते हुए कहा, "मैं आज मंच पर प्रस्तुत होने वाली हूँ, लेकिन मुझे थोड़ी घबराहट हो रही है।En: Hesitantly, Ananya said, "I am going to perform on stage today, but I am feeling a bit nervous."Hi: "राहुल ने सहानुभूति जताते हुए कहा, "मुझे भी कभी-कभी नए चित्र बनाते समय ऐसी भावना होती है।En: Rahul, expressing sympathy, said, "I sometimes feel that way when creating new paintings too.Hi: लेकिन याद रखो, कला दिल से आती है और दिल की सच्चाई को कोई छुपा नहीं सकता।En: But remember, art comes from the heart, and the truth of the heart cannot be hidden."Hi: "उनकी बातचीत धीरे-धीरे गहरी होती चली गई और वे दोनों अपने सपनों और संघर्षों को साझा करने लगे।En: Their conversation gradually deepened, and they began to share their dreams and struggles.Hi: इस संवाद ने अनन्या के भीतर एक आत्मविश्वास जगा दिया।En: This dialogue kindled a sense of confidence within Ananya.Hi: राहुल को भी ऐसा महसूस हुआ कि वह उसकी खोज के करीब आ गया है।En: Rahul too felt that he was getting closer to his search.Hi: शाम हुई, और अनन्या ने मंच पर अपनी प्रस्तुति शुरू की।En: Evening came, and Ananya began her performance on stage.Hi: जैसे ही उसने नृत्य करना आरंभ किया, उसकी हर मुद्राएं, हर भाव राहुल को मंत्रमुग्ध कर गईं।En: As soon as she started dancing, every gesture, every expression mesmerized Rahul.Hi: उसे वह प्रेरणा मिली, जो वह अरसे से तलाश रहा था।En: He found the inspiration he had been seeking for a long time.Hi: अनन्या के नृत्य ने न केवल दर्शकों को बल्कि राहुल के दिल को भी छू लिया।En: Ananya's dance touched not only the audience but also Rahul's heart.Hi: जब प्रदर्शन समाप्त हुआ और तालियों की गूंज थमी, राहुल ने अनन्या से जाकर कहा, "तुमने जो कला दिखाई, वह दिल को छू लेने वाली थी।En: When the performance ended and the applause subsided, Rahul approached Ananya and said, "The art you displayed was truly touching."Hi: "अनन्या ने उसकी तारीफ सुन मुस्कुराते हुए कहा, "धन्यवाद, तुमने जो आत्मविश्वास मुझे दिया, उसकी जरूरत थी।En: Ananya, smiling at his compliment, said, "Thank you, the confidence you gave me was much needed."Hi: "इस तरह, उस शाम ने उनके जीवन में एक नया मोड़ ला दिया।En: Thus, that evening brought a new turning point in their lives.Hi: अनन्या अपने डर पर विजय पाकर आत्मविश्वास से लबरेज हो गई, और राहुल को वह वास्तविक संबंध मिला जिसकी उसे तलाश थी।En: Ananya overcame her fear and became filled with confidence, and Rahul found the genuine connection he had been searching for.Hi: दोनों के बीच यह नई दोस्ती धीरे-धीरे एक गहरे रिश्ते में बदल गई, जो उनके जीवन में नई खुशियों की शुरुआत थी।En: This new friendship gradually transformed into a deep relationship, marking the beginning of new happiness in their lives.Hi: उत्सव की रौनक और वसंत की मस्ती ने उन्हें एक नई कहानी की शुरुआत को साकार होते देखा।En: The festival's grandeur and the joy of spring witnessed the start of a new story for them.Hi: अनन्या ने न केवल अपने डर को मात दी, बल्कि राहुल को भी एक नया दृष्टिकोण मिला।En: Ananya not only conquered her fear but also gave Rahul a new perspective.Hi: इस तरह, संगीत, नृत्य और कला के इस महोत्सव ने दो दिलों को आपस में जोड़ने का काम किया।En: In this way, the festival of music, dance, and art brought two hearts together. Vocabulary Words:fragrance: खुशबूmelodious: मधुरdelightful: खुशनुमाgrand: शानदारfestival: महोत्सवdecorate: सजावटpassionate: दीवानीshowcase: दिखानेeager: उत्सुकfear: डरdilemma: उलझनenvironment: माहौलconfidence: आत्मविश्वासinspiration: प्रेरणाhesitant: सहमतेmagnificent: शानदारnervous: घबराहटsympathy: सहानुभूतिgestures: मुद्राएंmesmerize: मंत्रमुग्धapplause: तालियोंtouching: छू लेने वालीcompliment: तारीफtransform: बदलperspective: दृष्टिकोणrelationship: रिश्तेgrandeur: रौनकconnection: संबंधstruggle: संघर्षgarments: वस्त्रों

This week on Cyrus Says, Cyrus catches up with theatre legends and long-time buddies Rahul daCunha and Bugs Bhargava—the brilliant minds behind the upcoming film Pune Highway. What starts as a movie promo somehow detours into Amul ad nostalgia, millionaire theories, their advertising days, and just maybe... a few drinks and drives (don’t try this at home). One of them even quit drinking. They’ve done plays, ads, life—and now a movie. Sort of. Pune Highway drops soon, find out if- Will Rahul sponsor the show? Will Bugs admit he's rich? And how deep does this decades-old friendship go? Watch till the end for some serious (and not-so-serious) bromance, behind-the-scenes madness, and vintage Cyrus Says mayhem.See omnystudio.com/listener for privacy information.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings. Episode Highlights: •⁠  ⁠The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making. •⁠  ⁠Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy. •⁠  ⁠Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy. •⁠  ⁠Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies. •⁠  ⁠Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies. Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

“Any sufficiently advanced technology is indistinguishable from magic.”In this episode of The Neon Show, Vishwa (Co-founder of ZenDuty) is joined by Rahul Sasi (Co-founder of CloudSEK) and Ananda Krishna (Co-founder of Astra Security). They share how AI feels magical now. And how as founders they are trying to sprinkle this magic everywhere from how building products to building teams and everything that matters.-------------00:00 Everything is being Reimagined!00:41 Meet the New Hosts01:08 Founders' Biggest Time Killer05:10 Why entrepreneurs should fail fast?11:19 Will your job inevitably change?17:40 How AI has reimagined engineering jobs?19:13 PMs & Designers have New workflows20:35 Why everyone should learn to Prompt?24:14 Is your team using AI Budgets efficiently?26:59 Do people trust AI chatbots?32:18 Does sales still need humans?35:53 Do we expect empathy from AI?-------------Check us out on:Website: https://neon.fund/Instagram: https://www.instagram.com/theneonshoww/LinkedIn: https://www.linkedin.com/company/beneon/Twitter: https://x.com/TheNeonShowwConnect with Siddhartha on:LinkedIn: https://www.linkedin.com/in/siddharthaahluwalia/Twitter: https://x.com/siddharthaa7-------------This video is for informational purposes only. The views expressed are those of the individuals quoted and do not constitute professional advice.Send us a text

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: •⁠  ⁠Overview of the treatment landscape for biliary tract cancer •⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue •⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care •⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions •⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

SpectraMedix helps health plans and systems navigate value-based contracts with technology that enhances administration, provider support, and data-driven decisions. In this episode, Rahul Lakhanpal, Chief of Staff, and Sean Kelly, Senior Vice President of Growth and Business Development at SpectraMedix, discuss how their organization is driving change in healthcare by focusing on value-based contract administration and management. They share insights into how SpectraMedix's platform helps health plans and health systems administer contracts, track performance, and translate contract terms into actionable insights for providers. Rahul and Sean also highlight how their technology differentiates itself by filtering information through the prism of the value-based contract, enabling better decision-making and improved outcomes in the evolving landscape of value-based care. Tune in and learn how SpectraMedix is transforming value-based care through contract administration, provider enablement, and data-driven insights! Resources: Connect with and follow Rahul Lakhanpal on LinkedIn. Follow and connect with Sean Kelly on LinkedIn. Learn more about SpectraMedix on their LinkedIn and website.

#nationalinterest ‘The announcement of caste census has come in the build-up to the Bihar elections. The census may conclude just ahead of the Uttar Pradesh elections. The reason we call this move a bad idea is because nobody has figured out what to do with the data, except Rahul Gandhi'— Watch this week's #NationalInterest with Shekhar Gupta --------------------------------------------------------------------------------------------- Read this week's National Interest: https://theprint.in/national-interest/caste-census-is-a-bad-idea-whose-time-has-come-much-worse-lies-ahead/2613185/ --------------------------------------------------------------------------------------------- To visit ThePrint Store: https://store.theprint.in/ --------------------------------------------------------------------------------------------- Produced By: Mahira Khan

This episode is a playbook for any curious 20-something in India dreaming of building the next big consumer electronics brand. Whether it's smartphones, earbuds, AI-powered glasses or health wearables, we dig into what it really takes to break into, and survive, this highly competitive space.I sat down with three brilliant minds in the game who've actually done it: Carl Pei (Co-Founder, Nothing), Rahul Sharma (Co-Founder, Micromax), and Amit Khatri (Co-Founder, Noise). We tried to decode the what, how, and WTF of this industry—from regulations and the fairness of trade tariffs, to startup realities and what disruption might look like next.You might just spot the next big idea as they share some untapped opportunities waiting to be built in this sector.Resource Document: https://iridescent-party-a15.notion.site/Consumer-Electronics-Resource-Document-1e1aef3ec3e980f29b86dd9bae34410dTimestamps:00:00 - Intro01:12 - How Apple sparked Carl's love for tech05:05 - The reason for Y Combinator's success07:28 - Carl's ‘lazy genius' approach towards his career15:05 - How Nothing differentiated itself16:36 - US tariff's impact on China, India & the industry (Note: Since this episode was recorded before recent changes to global trade & tariff policies, some views may not reflect current regulations.)22:10 - Carl's philosophical views on life24:23 - Rahul's journey & the roots of his entrepreneurial spirit29:30 - Micromax's early days: From payphones to GSM innovation38:23 - How traveling to villages led to Micromax's success50:47 - Competing with China & Micomax's manufacturing pivot1:00:00 - Apple's vertical integration strategy: Lessons for companies & governments1:05:00 - Learnings from Rahul's risk-taking & resilience1:09:00 - Amit's journey from education to building Noise1:23:34 - Roadmap for 20-somethings entering the electronics industry01:41:47 - Identifying gaps in the commodity market1:48:02 - Disruption in smartphones through design and AI opportunities1:57:40 - Today's youth vs. yesterday's corporations2:01:13 - Building India's supply chain & unlocking its market opportunity2:07:21 - An electronics launchpad for young entrepreneurs2:16:45 - India's semiconductor push & restarting efforts2:22:26 - Future of TV: One UI for all streaming apps?2:25:41 - Can India build a global ecosystem in electronics?2:35:58 - Health wearables & EdTech opportunities2:42:44 - Advice for 20-somethings who want to break into this industry#NikhilKamath - Investor & EntrepreneurTwitter: https://x.com/nikhilkamathcioLinkedIN: https://www.linkedin.com/in/nikhilkamathcio/ Instagram: https://www.instagram.com/nikhilkamathcio/ Facebook: https://www.facebook.com/nikhilkamathcio/ #CarlPei - CEO & Co-Founder, NothingTwitter: https://x.com/getpeidLinkedIN: https://www.linkedin.com/in/getpeid/Instagram: https://www.instagram.com/getpeid/Facebook: https://www.facebook.com/getpeid/ #RahulSharma - Co-Founder, MicromaxTwitter: https://x.com/rahulsharma LinkedIN: https://www.linkedin.com/in/rahul-sharma-83038634a/ #AmitKhatri - Co-Founder, NoiseTwitter: https://x.com/iamamitkhatri LinkedIN: https://www.linkedin.com/in/iamamitkhatri/Instagram: https://www.instagram.com/itsamitkhatri/

The healthcare system is broken — but Dr. Rahul Iyengar, (M.D.) isn't waiting around to fix it. In this eye-opening episode, we sit down with the founder of Members Health Co. to expose why traditional health insurance is failing us, how the medical system keeps people sick, and what it really means to live a healthy, empowered life.We talk about: ✅ The scam behind health insurance✅ Why doctors are burned out and patients are overlooked✅ A new model of care that puts YOU at the center✅ What you can do today to take control of your healthIf you've ever felt like the system isn't built for your well-being — this one's for you.Join the BA Family & follow us on Instagram.Check out the visual on Youtube. Join the free newsletter where you get exclusive access to mindset tips, events and a network of like minded individuals. The #1 Non-Synthetic Supplement for anti-aging, skin, sleep, libido & recovery. Use code "breathinair"

Rahul Vohra (Founder and CEO at Superhuman) joins SaaStock's Alex Theuma to discuss how Superhuman stayed ahead of the generative AI wave, how they're shaping the future of productivity with autonomous email agents, and why great products that delights users — not flashy marketing — are the key to viral growth. Rahul also opens up about the loneliness of being a CEO, his meditation practices, and the game design principles behind Superhuman's success. Check out the other ways SaaStock is helping SaaS founders move their business forward: 

This week, we have Rahul Sonwalkar, Founder and CEO of Julius, on the show. Julius is your AI Data Scientist, where users can quickly analyze, visualize, and transform data.Rahul covers his journey from traveling across the country to hackathons in college, the importance of not being afraid of failing as a founder, how Rahul seeks out mentors, the four key ways Julius delivers value, and how Julius continues to add AI to data analysis.We also cover the decision to start selling bottoms up, how that enabled revenue in the early days, and how smarter models directly benefit Julius.Episode Chapters:Undergrad at UT Dallas - 1:47Being okay with being wrong - 4:18Overcoming ego - 7:15The Julius DNA - 9:20Your AI data analyst - 12:15Building trust with Julius - 15:30Maintaining infrastructure - 19:20Building out new features - 22:32Two kinds of AI startups - 27:13The next wave of SEO - 29:07Assessing talent - 32:12 Quick fire round - 33:26As always, feel free to contact us at partnerpathpodcast@gmail.com. We would love to hear ideas for content, guests, and overall feedback.This episode is brought to you by Grata, the world's leading deal sourcing platform. Our AI-powered search, investment-grade data, and intuitive workflows give you the edge needed to find and win deals in your industry. Visit grata.com to schedule a demo today.Fresh out of Y Combinator's Summer batch, Overlap is an AI-driven app that uses LLMs to curate the best moments from podcast episodes. Imagine having a smart assistant who reads through every podcast transcript, finds the best parts or parts most relevant to your search, and strings them together to form a new curated stream of content - that is what Overlap does. Podcasts are an exponentially growing source of unique information. Make use of it! Check out Overlap 2.0 on the App Store today.

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients. In this episode, we covered: •⁠  ⁠The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers. •⁠  ⁠The complexities of biomarker testing, including NGS, IHC, and FISH amplification. •⁠  ⁠Patient characteristics and phenotypes associated with HER2-positive disease. •⁠  ⁠The current testing workflows in clinical practice and the role of liquid biopsies. •⁠  ⁠Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment. YouTube: https://youtu.be/gMi-sflQyQo Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!

Rahul Pangam — Entrepreneur, AI Strategist, and Founder

Order my newest book Make Money Easy! https://lewishowes.com/moneyyouCheck out the full episode: greatness.lnk.to/1754"The dreaming brain is hyper emotional and hyper visual with dampened logic. It also locks down your body so you're temporarily paralyzed so the dreaming brain can let loose, be emotional, be wild." - Dr. Rahul JandialNeuroscientist Dr. Rahul Jandial takes us on a fascinating journey through the mysterious world of sleep paralysis and lucid dreaming. He explains the science behind those terrifying moments when you wake up unable to move—a phenomenon experienced by one-third of people worldwide. With remarkable clarity, Dr. Jandial breaks down how our brains transition between waking and dreaming states, revealing why these transitions sometimes overlap and create experiences so profound they've inspired cultural myths across civilizations.Delving deeper into the neuroscience of dreams, Dr. Jandial explores how our dreaming brain becomes hyper-emotional and hyper-visual while dampening logic. He unpacks the fascinating chemical processes that temporarily paralyze our bodies during sleep and how the misalignment between mind awakening and body releasing can create extraordinary experiences. Whether you've experienced sleep paralysis yourself or are curious about harnessing the power of lucid dreaming, this conversation offers invaluable insights into the complex relationship between your waking and dreaming consciousness.Sign up for the Greatness newsletter: http://www.greatness.com/newsletter

Jason and Rahul Sen Sharma, an expert on indexes from Index (INDXX), discuss global economic shifts, trade wars, and the stock market. His company tracks over $20 billion in index-based assets, aiding companies in creating indexes, ETFs, and funds. He emphasizes focusing on long-term macro trends over daily market noise, highlighting "re-globalization" as a key shift driven by supply chain vulnerabilities and a desire for friendly-shoring and near-shoring. While tariffs may offer short-term benefits to some countries like India and Mexico, the focus should be on transformative trends like EVs, battery tech, renewables, and critical metals for long-term investment. He also touches on the importance of understanding index rulebooks due to performance divergences and addresses concerns about the S&P 500's concentration, suggesting the marketplace will dictate the need for alternative weighting. https://www.indxx.com/ #Indexes #Economy #TradeWar #Tariffs #StockMarket #Globalization #Reglobalization #Friendshoring #Nearshoring #Investment #Finance #ETFs #MarketTrends #Macroeconomics #RahulSenSharma #INDXX Key Takeaways: 1:28 Meet Rahul 2:16 Broad strokes and taking a macro view 5:11 Reglobalization 7:49 Level playing field 9:43 Where do we go from here 13:16 A difference in indexes 16:24 Self-indexing and the active managers 20:50 The big picture perspective   Follow Jason on TWITTER, INSTAGRAM & LINKEDIN Twitter.com/JasonHartmanROI Instagram.com/jasonhartman1/ Linkedin.com/in/jasonhartmaninvestor/ Call our Investment Counselors at: 1-800-HARTMAN (US) or visit: https://www.jasonhartman.com/ Free Class:  Easily get up to $250,000 in funding for real estate, business or anything else: http://JasonHartman.com/Fund CYA Protect Your Assets, Save Taxes & Estate Planning: http://JasonHartman.com/Protect Get wholesale real estate deals for investment or build a great business – Free Course: https://www.jasonhartman.com/deals Special Offer from Ron LeGrand: https://JasonHartman.com/Ron Free Mini-Book on Pandemic Investing: https://www.PandemicInvesting.com    

Here's the thing: we all heard Sundar Pichai say that the easy wins in AI have faded and that we may see fewer headline‑grabbing releases from the big players over the next year. That comment feels like a red flag for momentum, but I see it as a green light for action.  In this episode, I chatted with Rahul Pradhan, VP of Product and Strategy at Couchbase, about how teams can take advantage of this pause to move projects from simple experiments into solid, production‑ready services. I ask why many organizations hesitate to send their data to public AI endpoints. Rahul explains that when you've invested years building data platforms, handing over your proprietary information—even in encrypted form—can feel like handing over the keys to your kingdom. He walks us through how running models inside your security perimeter keeps private data safe and brings up model accuracy since you can tailor inputs and scrub out noise before it ever reaches the inference engine. Next, we tackle the question of stability. Companies often assume that the path to a live service is straightforward once a pilot works. Rahul warns that managing GPUs, orchestrating models, and serving them at low latency all require skill sets that live at the crossroads of ML engineering and traditional software development. We round out our conversation by shifting focus from tools to teams. Technology alone cannot carry an AI initiative. We need leaders who set a clear vision, data stewards who govern every data flow, and developers who feel as comfortable writing database queries as they define training pipelines. Rahul offers thoughtful advice on building that culture and shares examples of industries—healthcare, financial services, and retail—where the most far‑reaching uses of AI are taking root. If you're wondering how to push your proof of concept into a robust service that customers depend on, this episode is for you. I promise you'll come away with ideas you can apply tomorrow and a fresh view of why a little breathing room in AI releases can become the launch pad for your subsequent big success.    

Rahul Vohra is the founder and CEO of Superhuman. Prior to Superhuman, Rahul founded Rapportive, the first Gmail plug-in to scale to millions of users, which he sold to LinkedIn in 2012. He is also a prominent angel investor, and his fund has invested $50 million in over 120 companies, including Placer, Supabase, Mercury, Zip, ClassDojo, and Writer.What you'll learn:• The unexpected insight about virality Rahul gained from LinkedIn's head of growth.• Why Rahul restructured his entire executive team to spend 60% to 70% of his time on product, design, and marketing instead of the typical CEO responsibilities.• The counterintuitive approach to finding product-market fit using a methodical system inspired by Sean Ellis, and how this algorithmically determines your roadmap.• How manually onboarding every user (Superhuman had 20 full-time people doing this at peak) created superfans and allowed engineers to focus on product rather than onboarding flows.• The “Single Decisive Reason” framework for making better decisions by avoiding collections of weak justifications.• How Superhuman's AI features have evolved to create a truly intelligent email experience that works while you sleep.—Brought to you by:• Eppo—Run reliable, impactful experiments• Fundrise Flagship Fund—Invest in $1.1 billion of real estate• OneSchema—Import CSV data 10x faster—Find the transcript at: https://www.lennysnewsletter.com/p/superhumans-secret-to-success-rahul-vohra—Where to find Rahul Vohra:• X: https://x.com/rahulvohra• LinkedIn: https://www.linkedin.com/in/rahulvohra/• Email: Rahul@superhuman.com—Where to find Lenny:• Newsletter: https://www.lennysnewsletter.com• X: https://twitter.com/lennysan• LinkedIn: https://www.linkedin.com/in/lennyrachitsky/—In this episode, we cover:(00:00) Introduction to Rahul and Superhuman(05:00) The most pivotal moment in Rahul's career(07:01) The secret to virality(11:02) Superhuman's product evolution and core values(13:32) Overcoming slowdowns at scale(18:06) Time management and meditation(27:35) The role of a president(30:56) Attention to detail(43:00) Finding your unique position(47:32) The power of manual onboarding(52:37) Mastering product-market fit(59:33) Game design in business software(01:05:35) Contrarian pricing strategies(01:09:29) Leveraging AI(01:15:40) Transitioning to enterprise solutions(01:19:08) The Single Decisive Reason framework(01:22:32) Conclusion and final thoughts—Referenced:• Superhuman: https://superhuman.com/• Rapportive: https://techcrunch.com/2012/02/22/rapportive-linkedin-acquisition/• Elliot Shmukler on LinkedIn: https://www.linkedin.com/in/eshmu/• What Are ‘Whales' in Video Games: https://gamerant.com/video-games-whales-concept-term-explained/• Figma: https://www.figma.com/• Notion: https://www.notion.com/• Loom: https://www.loom.com/• How to use Team Comments to reimagine email collaboration: https://blog.superhuman.com/how-to-use-team-comments-to-reimagine-email-collaboration/• Rajiv Ayyangar's post on X about Superhuman: https://x.com/rajivayyangar/status/1816176308130570385• Transcendental Meditation: https://www.tm.org/• Laurent Valosek on LinkedIn: https://www.linkedin.com/in/laurent-valosek-18708b5a/• Peak Leadership Institute: https://www.peakleadershipinstitute.com/• Ed Sim's website: https://edsim.net/• Adelle Sans: https://fonts.adobe.com/fonts/adelle-sans• Comic Sans: https://en.wikipedia.org/wiki/Comic_Sans• Greenfield project: https://en.wikipedia.org/wiki/Greenfield_project• Why Mailbox died: https://www.theverge.com/2015/12/8/9873268/why-dropbox-mailbox-shutdown• Bill Trenchard on X: https://x.com/btrenchard• How Superhuman Built an Engine to Find Product-Market Fit: https://review.firstround.com/how-superhuman-built-an-engine-to-find-product-market-fit/• Using the Sean Ellis Test for Measuring Your Product-Market Fit: https://medium.productcoalition.com/using-sean-ellis-test-for-measuring-your-product-market-fit-c8ac98053c2c• Sean Ellis on LinkedIn: https://www.linkedin.com/in/seanellis/• The original growth hacker reveals his secrets | Sean Ellis (author of “Hacking Growth”): https://www.lennysnewsletter.com/p/the-original-growth-hacker-sean-ellis• The Trouble with Rewards: https://www.kornferry.com/insights/briefings-magazine/issue-13/519-the-trouble-with-rewards• The art and science of pricing | Madhavan Ramanujam (Monetizing Innovation, Simon-Kucher): https://www.lennysnewsletter.com/p/the-art-and-science-of-pricing-madhavan•  Van Westendorp Price Sensitivity Meter: https://en.wikipedia.org/wiki/Van_Westendorp%27s_Price_Sensitivity_Meter• AI-powered email for high-performing teams: https://superhuman.com/ai• Linear's secret to building beloved B2B products | Nan Yu (Head of Product): https://www.lennysnewsletter.com/p/linears-secret-to-building-beloved-b2b-products-nan-yu• Single Decisive Reason: decision-making for fast-scaling startups: https://blog.superhuman.com/single-decisive-reason-decision-making-for-fast-scaling-startups/• Reid Hoffman on LinkedIn: https://www.linkedin.com/in/reidhoffman/—Recommended books:• Positioning: The Battle for Your Mind: https://www.amazon.com/Positioning-Battle-Your-Al-Ries/dp/0071373586• Monetizing Innovation: How Smart Companies Design the Product Around the Price: https://www.amazon.com/Monetizing-Innovation-Companies-Design-Product/dp/1119240867—Production and marketing by https://penname.co/. For inquiries about sponsoring the podcast, email podcast@lennyrachitsky.com.—Lenny may be an investor in the companies discussed. Get full access to Lenny's Newsletter at www.lennysnewsletter.com/subscribe

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.